Parkwoods Wealth Partners LLC Buys New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Parkwoods Wealth Partners LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,001 shares of the biopharmaceutical company’s stock, valued at approximately $211,000. TG Therapeutics accounts for about 0.2% of Parkwoods Wealth Partners LLC’s investment portfolio, making the stock its 29th largest holding.

A number of other institutional investors have also modified their holdings of TGTX. The Manufacturers Life Insurance Company lifted its stake in shares of TG Therapeutics by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 80,664 shares of the biopharmaceutical company’s stock valued at $1,435,000 after purchasing an additional 2,871 shares during the period. Algert Global LLC raised its position in shares of TG Therapeutics by 193.8% in the second quarter. Algert Global LLC now owns 147,218 shares of the biopharmaceutical company’s stock worth $2,619,000 after acquiring an additional 97,118 shares during the period. Creative Planning raised its position in shares of TG Therapeutics by 34.7% in the second quarter. Creative Planning now owns 46,839 shares of the biopharmaceutical company’s stock worth $833,000 after acquiring an additional 12,076 shares during the period. Quarry LP boosted its stake in shares of TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of TG Therapeutics during the 2nd quarter valued at about $10,423,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,358 shares of company stock worth $781,497 in the last ninety days. Insiders own 10.50% of the company’s stock.

TG Therapeutics Trading Up 0.7 %

Shares of TGTX stock opened at $33.70 on Wednesday. TG Therapeutics, Inc. has a fifty-two week low of $12.84 and a fifty-two week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock’s fifty day moving average is $31.68 and its two-hundred day moving average is $26.36. The firm has a market capitalization of $5.25 billion, a P/E ratio of -335.72 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the prior year, the business posted $0.73 earnings per share. The business’s quarterly revenue was down 49.4% on a year-over-year basis. Research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.